Table 1.

Summary Table of Studies Evaluating Risk of Cervical High-Grade Dysplasia/Cancer in IBD patients on immunosuppressive medications.

Source	Country	Study Type	# IBD with dysplasia/cancer	# IBD Total	Inclusion Criteria	Medications Used
Kim, 2014	US	Cohort	59	25176	Women age ≥18 with SID, including IBD based on (ICD-9) codes with ≥1 disease specific medication prescription	IM, steroids
Bhatia, 2006	US	Cohort	4	116	Women age 18-80 with confirmed IBD and at least one Pap smear in the previous five years for inclusion in the study	IM, steroids, biologics
Kane, 2008	US	Case control	15	40	Female patients with a history of IBD with a confirmed normal Pap smear prior to IBD diagnosis	IM, steroids
Lees, 2009	Scotland	Case control	25	362	Women with a diagnosis of IBD prior to age 60	IM, biologics
Marehbian, 2009	US	Cohort	70	22310	Patients with at least one claim for crohn’s disease by ICD-9 codes	IM, steroids, biologics
Hutfless, 2008	US	Cohort	10	1165	women age 15–68 with confirmed IBD from January 1996 to 30 June 2006	IM, steroids, biologics
Rungoe, 2014	Denmark	Cohort	678	27408	Women with a confirmed diagnosis of either UC or CD after January 1, 1979 residing in Denmark	IM, steroids, biologics
Singh 2009	Canada	Case control	134	539	Women ≥18 from Manitoba who had an abnormal Pap test result between Jan. 2002 and Dec. 2006.	IM, steroids